Drug profile

The FDA adverse-event record for Feline Calicivirus + Rhinotracheitis Virus + Panleukopenia Vaccine

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Feline Calicivirus + Rhinotracheitis Virus + Panleukopenia Vaccine. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
11.8%
death-coded share
Cat
most-reported species
5
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
2
Deaths Reported
11.8%
Death Rate

Active Ingredients

Feline Calicivirus + Rhinotracheitis Virus + Panleukopenia Vaccine

Administration Routes

UnknownSubcutaneousParenteral

Species Affected

Cat 17

Most Affected Breeds

Domestic Shorthair 14
Domestic Longhair 3

Most Reported Reactions

Vomiting 5
Behavioural disorder NOS 4
Lethargy (see also Central nervous system depression in Neurological) 4
Sneezing 3
Hypotension 3
Hyperglycaemia 3
Injection site sarcoma 3
Lack of efficacy (ectoparasite) - flea 2
Skin reaction NOS 2
Death 2
Anorexia 2
Not drinking 2

Outcome Breakdown

Recovered/Normal
5 (29.4%)
Outcome Unknown
5 (29.4%)
Ongoing
5 (29.4%)
Died
2 (11.8%)

Feline Calicivirus + Rhinotracheitis Virus + Panleukopenia Vaccine Adverse Event Insights

17 reports name Feline Calicivirus + Rhinotracheitis Virus + Panleukopenia Vaccine; 2 recorded a death outcome (11.8% of reported events, not a population-level mortality rate). Active ingredient: Feline Calicivirus + Rhinotracheitis Virus + Panleukopenia Vaccine. Administration routes: Unknown, Subcutaneous, Parenteral.

By species: Cat (17 reports). By breed: Domestic Shorthair (14), Domestic Longhair (3).

Leading clinical signs: Vomiting (5), Behavioural disorder NOS (4), Lethargy (see also Central nervous system depression in Neurological) (4), Sneezing (3). Outcome, 17 coded reports: Recovered/Normal leads at 29.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.